Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 6/20 | 0.55 |
| ▸ | GBA1 | P04062 | 8/20 | 0.53 |
| ▸ | ROS1 | P08922 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.47 |
| ▸ | GSK3A | P49840 | 1/20 | 0.46 |
| ▸ | GSK3B | P49841 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14727599 | 0.95 | PDE5A (0.57) | PDE5AGBA1MEN1KMT2AALDH1A1 | |
| SCHEMBL16183741 | 0.89 | GBA1 (0.59) | PDE5AGBA1MEN1KMT2AALDH1A1 | |
| SCHEMBL14474100 | 0.87 | PDE5A (0.61) | PDE5AGBA1ALDH1A1LMNACYP1A2 | |
| SCHEMBL14727823 | 0.86 | PDE5A (0.62) | PDE5AGBA1MEN1KMT2AALDH1A1 | |
| SCHEMBL16184588 | 0.85 | ROS1 (0.48) | PDE5AGBA1ROS1MEN1KMT2A | |
| SCHEMBL14727595 | 0.84 | CYP1A2 (0.55) | PDE5AGBA1MEN1KMT2AALDH1A1 | |
| SCHEMBL16183747 | 0.83 | CYP1A2 (0.61) | PDE5AGBA1MEN1KMT2AALDH1A1 | |
| SCHEMBL14475213 | 0.83 | CYP1A2 (0.59) | PDE5AGBA1MEN1KMT2AALDH1A1 | |
| SCHEMBL14475219 | 0.83 | PDE5A (0.60) | PDE5AGBA1MEN1KMT2AALDH1A1 | |
| SCHEMBL17212398 | 0.82 | GBA1 (0.61) | PDE5AGBA1MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170217923-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-08-03 | — | — | US | disclosed |
| US-20170217923-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-08-03 | — | — | US | disclosed |
| EP-3056207-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | Otsuka Pharmaceutical Co., Ltd. (JP) | 2016-08-17 | — | — | EP | disclosed |
| US-20150307477-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | GALENEA CORPORATION | 2015-10-29 | — | — | US | disclosed |
| US-20150307477-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | GALENEA CORPORATION | 2015-10-29 | — | — | US | disclosed |
| US-20140315886-A1 | QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-10-23 | — | — | US | disclosed |
| US-20140315886-A1 | QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-10-23 | — | — | US | disclosed |
| US-20130053341-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL COMPANY (JP) | 2013-02-28 | — | — | US | disclosed |
| US-20130053341-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL COMPANY (JP) | 2013-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150307477-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | PPP4C, PTPRG, PPP2CA | PDE5A 748/4885GBA1 304/4885ROS1 645/4885 |
| US-20130053341-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | PPP4C, PPP3CB, PTPRG | PDE5A 979/4885GBA1 853/4885ROS1 611/4885 |
| US-20170217923-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | PPP4C, PTPRG, PPP2CA | PDE5A 748/4885GBA1 304/4885ROS1 645/4885 |
| US-20140315886-A1 | QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | PPP2CA, PPP4C, PPP3CB | PDE5A 704/4885GBA1 1316/4885ROS1 802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.